Mantle Cell Lymphoma Clinical Trials in Salt Lake City, Utah

5 studies are recruiting for mantle cell lymphoma in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

   This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody th…

   Stage

   Phase 3

   Ages

   60 and older

   Site

   Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

   Locations

   238 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05976763 on ClinicalTrials.gov

2. Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

   This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability …

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT05861050 on ClinicalTrials.gov

3. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

   This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

   Locations

   4 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04775745 on ClinicalTrials.gov

4. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

   This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Utah, Salt Lake City, Utah

   Locations

   7 in total

   Run by

   CRISPR Therapeutics AG

   See if you can join NCT05643742 on ClinicalTrials.gov

5. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Salt Lake City, Utah

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov